Table 2.
AMP expression in gynecological cancers.
| Gynecological Cancers | Expression Increased | Expression Decreased | Refs. | ||
|---|---|---|---|---|---|
| Protein | mRNA | Protein | mRNA | ||
| Epithelial ovarian cancer- tissues | HD5, hCAP-18/LL-37, SLPI, elafin, HE4, S100A7, lactoferrin | HD5, SLPI, elafin, calprotectin, HE4, S100A7, SP-D | [59,66,68,70,71,73,82,83,84,85,86,87] | ||
| Epithelial ovarian cancer- serum samples | SLPI, calprotectin, HE4 | [59,61,62,63,88] | |||
| Epithelial ovarian cancer-circulating tumor cells | SP-D | [71] | |||
| Clear cell ovarian cancer- tissues | HE4 | HE4 | [85] | ||
| Ovarian cancer cell lines (HEY cells, SKOV-3 cells and OV-90 cells) | hCAP-18/LL-37 | [87] | |||
| Ovarian cancer cell lines (Caov3 cells and SKOV3 cells) | S100A7 | [68] | |||
| Cystic fluid of epithelial ovarian cancer | S100A8/S100A9 | [86] | |||
| SCC (Squamous cervical cancer) --biopsies |
HBD3, S100A9, S100A7 | HBD2, elafin | HBD2, elafin | [12,57,58,89,90] | |
| HSIL (high-grade squamous intraepithelial lesions)- biopsies |
HBD2 | HBD2 | [89] | ||
| Cervical cancer cell lines (SiHa, CasKi and KT1 cells) | HBD2 | HBD2 | [89] | ||
| Cervical cancer cell lines (HeLa, CaSki, and SiHa cells) | HBD3 | HBD3 | [12] | ||
| Cervical adenocarcinoma-tissues | SLPI | [56] | |||
| Endometrioid cancer-tissues | HE4 | HE4 | [60] | ||
| Papillary serous endometrial cancer-tissues | HE4 | HE4 | [60,67] | ||
| Clear cell carcinoma of the uterus-tissues | HE4 | HE4 | [60] | ||
| Xenograft endometrial cancer-tissues |
HE4 | HE4 | [91] | ||
| Endometrial carcinoma -serum samples |
calprotectin | [64], | |||
| Vulvar Paget’s Disease-related vulvar cancer tissues | HE4 | [76] | |||
| Vulvar squamous cell cancer-tissues | S100A7, SLPI | [65,72] | |||
| Leiomyosarcoma- serum samples |
HE4 | [80,81] | |||